Trials / Completed
CompletedNCT04060173
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671
A Randomized, Double-Blind, Placebo-Controlled Phase 1b Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 Administered Orally for 10 Days in Subjects With Hyperuricemia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Atom Therapeutics Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of ABP-671 administered orally in subjects with hyperuricemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABP-671 | ABP-671 is an investigational drug |
| OTHER | Placebo | Matching placebo |
Timeline
- Start date
- 2019-09-05
- Primary completion
- 2019-12-29
- Completion
- 2020-02-07
- First posted
- 2019-08-19
- Last updated
- 2020-02-12
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04060173. Inclusion in this directory is not an endorsement.